Advertisement
Singapore markets closed

  • Straits Times Index

    3,187.66
    +32.97 (+1.05%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • Dow

    37,753.31
    -45.66 (-0.12%)
     

  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     

  • Bitcoin USD

    62,170.16
    -301.96 (-0.48%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • FTSE 100

    7,859.97
    +11.98 (+0.15%)
     

  • Gold

    2,397.70
    +9.30 (+0.39%)
     

  • Crude Oil

    82.28
    -0.41 (-0.50%)
     

  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     

  • Nikkei

    38,079.70
    +117.90 (+0.31%)
     

  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     

  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     

  • Jakarta Composite Index

    7,166.81
    +35.97 (+0.50%)
     

  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Company News for Nov 29, 2019

Zacks Equity Research

  • Shares of Diplomat Pharmacy, Inc. DPLO gained 12.1% after the company posted revenues of $1.3 billion for third-quarter 2019, beating the Zacks Consensus Estimate by 11.8%.

  • Shares of Box, Inc. BOX rose 11.5% after the company reported total revenues of $177.16 million in Q3, which surpassed the Zacks Consensus Estimate of $174.5 million.

  • Shares of Central Garden & Pet Company CENT declined 17.5% after the company reported fourth-quarter fiscal 2019 earnings of 4 cents a share, which lagged the Zacks Consensus Estimate of 17 cents.

  • Shares of Evolent Health, Inc. EVH lost 27.3% after Passport Health, which is owned by Evolent Health, couldn’t secure prominent Medicaid contracts in Kentucky.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Box, Inc. (BOX) : Free Stock Analysis Report
 
Evolent Health, Inc (EVH) : Free Stock Analysis Report
 
Central Garden & Pet Company (CENT) : Free Stock Analysis Report
 
Diplomat Pharmacy, Inc. (DPLO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research